PD Dr. Markus Eckstein

Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie Institute of Pathology

Primary results of the phase II CheckRad-CD8 trial: First-line treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+T-cell infiltration. (2021) Hecht M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Klautke G, Laban S, et al. Conference contribution Integration of spatial pd-l1 expression with the tumor immune microenvironment outperforms standard pd-l1 scoring in outcome prediction of urothelial cancer patients (2021) Weyerer V, Strissel P, Strick R, Sikic D, Geppert CI, Bertz S, Lange F, et al. Journal article, Original article Endogenous Retroviral-K Envelope Is a Novel Tumor Antigen and Prognostic Indicator of Renal Cell Carcinoma (2021) Weyerer V, Strissel P, Stohr C, Eckstein M, Wach S, Taubert H, Brandl L, et al. Journal article, Original article Implementation of double immune checkpoint blockade increases response rate to induction chemotherapy in head and neck cancer (2021) Semrau S, Gostian AO, Traxdorf M, Eckstein M, Rutzner S, von der Grün J, Illmer T, et al. Journal article Bladder Tumor Subtype Commitment Occurs in Carcinoma In Situ Driven by Key Signaling Pathways Including ECM Remodeling (2021) Wullweber A, Strick R, Lange F, Sikic D, Taubert H, Wach S, Wullich B, et al. Journal article Immune checkpoint inhibitors in urothelial carcinoma: Recommendations for practical approaches to pd-l1 and other potential predictive biomarker testing (2021) Lopez-Beltran A, López-Rios F, Montironi R, Wildsmith S, Eckstein M Journal article, Review article Tumour‐infiltrating lymphocytes (Tils) and pd‐l1 expression correlate with lymph node metastasis, high‐grade transformation and shorter metastasis‐free survival in patients with acinic cell carcinoma (acicc) of the salivary glands (2021) Hiß S, Eckstein M, Segschneider P, Mantsopoulos K, Iro H, Hartmann A, Agaimy A, et al. Journal article Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors (2021) Zhou J, Donaubauer AJ, Frey B, Becker I, Rutzner S, Eckstein M, Sun R, et al. Journal article, Review article Tert promoter mutation analysis of whole-organ mapping bladder cancers (2021) Weyerer V, Eckstein M, Strissel P, Wullweber A, Lange F, Tögel L, Geppert CI, et al. Journal article Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy (2021) Taubert H, Eckstein M, Epple E, Jung R, Weigelt K, Lieb V, Sikic D, et al. Journal article